Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Endocrinology · Gastrinoma

Your Path Forward: Long-Term Monitoring and Survivorship

At a Glance

After gastrinoma surgery, follow-up often continues for years or lifelong because tumors can recur. Monitoring may include gastrin blood tests, CT or MRI scans, MEN1-related checks, and review of long-term PPI effects, while care also addresses scan-related anxiety and quality of life.

Surviving a gastrinoma diagnosis means moving into a phase of long-term vigilance. Because these tumors can be slow-growing and sometimes return even after successful surgery, management usually lasts for decades. Your goal now is to balance effective monitoring with a high quality of life [1][2].

The Necessity of Lifelong Monitoring

Even if your surgery was considered “curative,” gastrinomas have a persistent way of reappearing years later. In many cases, patients may see a rise in gastrin levels or have a tumor visible on scans years after surgery. Recurrence risk is highly dependent on whether the disease is sporadic or MEN1-associated, the primary site, and the tumor grade [1][3].

Because of this, surveillance is not just a short-term checkup; it is an ongoing process. A typical schedule often includes:

  • Years 1–3: Tailored blood tests for gastrin and cross-sectional imaging (CT or MRI) based on your individual risk factors and primary site [4][5].
  • Years 4–10 and beyond: If you remain stable, scans may be spaced out further, but follow-up rarely stops entirely. Some patients eventually undergo a second surgery (reoperation) to remove recurrent disease, which can lead to many more years of being tumor-free [6].

If you have MEN1, surveillance changes materially. It requires a comprehensive plan that includes regular checks of your blood calcium and parathyroid hormone (PTH), pituitary function assessments, abdominal imaging, and family cascade testing for relatives who may carry the gene [7][8].

Managing the Risks of “The Shield”

For many, taking high-dose Proton Pump Inhibitors (PPIs) is a lifelong requirement to prevent life-threatening acid damage [9], though post-resection needs can vary. While these drugs are your primary defense, taking them in high doses for years requires its own set of monitoring [7]:

  • Vitamin B12 Deficiency: Some ZES patients on long-term acid suppression develop a B12 deficiency because stomach acid is needed to absorb this vitamin from food [10]. Symptoms can include fatigue or tingling in the hands and feet.
  • Magnesium Levels: In rare cases, PPIs can cause the body to lose magnesium, which can lead to muscle cramps or heart rhythm issues [11][12].
  • Kidney Health: Long-term use has been linked in some observational studies to a higher risk of chronic kidney disease [11][13]. Monitoring frequency is individualized, so discuss testing your creatinine and eGFR (kidney function) with your team. Routine testing is not automatically necessary for everyone.

Navigating “Scanxiety” and Quality of Life

Living with a chronic condition that requires constant testing takes a psychological toll. Scanxiety—the intense anxiety felt before and during medical imaging—is a real and common experience for neuroendocrine tumor survivors [4].

  • Imaging Choices: While Ga-68 DOTATATE PET/CT is excellent for finding tumors, your doctor may not use it every year to avoid unnecessary radiation exposure, especially if your disease is stable [14].
  • Diet and Weight: Many patients struggle with weight loss during the diagnostic phase. Once acid is controlled, weight recovery varies but is common [15]. You generally do not need a highly restrictive diet, but you should work with your team to manage any lingering diarrhea or reflux symptoms [16].

The “new normal” of gastrinoma survivorship is about staying one step ahead of the disease while ensuring that the treatments themselves don’t become a burden. Consistent communication with a specialized neuroendocrine tumor team is the best way to navigate these long-term trade-offs [17][18].

Common questions in this guide

How long will I need follow-up after gastrinoma surgery?
Follow-up often continues for many years and may be lifelong because a gastrinoma can return even after surgery that was considered curative. The timing of gastrin blood tests and CT or MRI scans depends on your recurrence risk, tumor grade, primary site, and whether MEN1 is involved.
Which scans and blood tests are used to monitor gastrinoma?
Your team may monitor gastrin levels with blood tests and use CT or MRI scans to look for recurrent disease. A Ga-68 DOTATATE PET/CT may be useful in selected situations, but it may not be needed every year when the disease is stable.
What extra follow-up is needed for gastrinoma with MEN1?
MEN1 follow-up may include checks of blood calcium and parathyroid hormone, pituitary function testing, and abdominal imaging. Close relatives may also be offered genetic testing to learn whether they carry the MEN1 gene.
What should be checked during long-term high-dose PPI treatment?
Your clinician may review vitamin B12, magnesium, and kidney function, including creatinine and eGFR, because long-term acid suppression can affect these measures in some people. Testing schedules are individualized, and routine testing is not automatically necessary for everyone.
Can I reduce my PPI dose after gastrinoma surgery?
Some people need high-dose PPIs for life to prevent dangerous acid damage, while needs may change after tumor removal. Do not lower or stop the medicine on your own; ask your team whether a maintenance dose would be safe.
How can I cope with anxiety before gastrinoma scans?
Scanxiety, or intense anxiety before and during imaging, is common among neuroendocrine tumor survivors. Tell your care team how you are feeling and arrange support from family, friends, or another trusted person around scan appointments.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor's size and grade, what is my specific risk of recurrence?
  2. 2.How often should I have my vitamin B12, magnesium, and kidney function (creatinine) checked while on high-dose PPIs?
  3. 3.What is our individualized plan for imaging (CT, MRI, or PET/CT) over the next few years?
  4. 4.If my gastrin levels begin to rise, at what threshold would you consider a change in treatment or a reoperation?
  5. 5.Can we review my PPI dose periodically to see if we can safely reach a 'maintenance' level while still protecting my stomach?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    [Management of gastrinoma].

    Hain E, Coriat R, Dousset B, Gaujoux S

    Presse medicale (Paris, France : 1983) 2016; (45(11)):986-991 doi:10.1016/j.lpm.2016.04.012.

    PMID: 27262229
  2. 2

    Primary lymph node gastrinoma: A single institution experience.

    Chen Y, Deshpande V, Ferrone C, et al.

    Surgery 2017; (162(5)):1088-1094 doi:10.1016/j.surg.2017.05.017.

    PMID: 28705492
  3. 3

    Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1.

    Albers MB, Manoharan J, Bollmann C, et al.

    World journal of surgery 2019; (43(2)):552-558 doi:10.1007/s00268-018-4809-1.

    PMID: 30288555
  4. 4

    Imaging of neuroendocrine tumors of the pancreas.

    Dromain C, Déandréis D, Scoazec JY, et al.

    Diagnostic and interventional imaging 2016; (97(12)):1241-1257 doi:10.1016/j.diii.2016.07.012.

    PMID: 27876341
  5. 5

    Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.

    Rossi RE, Elvevi A, Citterio D, et al.

    World journal of gastroenterology 2021; (27(35)):5890-5907 doi:10.3748/wjg.v27.i35.5890.

    PMID: 34629807
  6. 6

    Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome.

    Norton JA, Krampitz GW, Poultsides GA, et al.

    Annals of surgery 2018; (267(4)):782-788 doi:10.1097/SLA.0000000000002122.

    PMID: 29517561
  7. 7

    Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome-Clues to a Safer Diagnostic Process.

    Singh Ospina N, Donegan D, Rodriguez-Gutierrez R, et al.

    The American journal of medicine 2017; (130(5)):603-605 doi:10.1016/j.amjmed.2016.11.035.

    PMID: 28011308
  8. 8

    Multiple Endocrine Neoplasia Type 1 (MEN1) Presenting as an Invasive Macroprolactinoma Complicated by Acute Bacterial Meningitis.

    Bandaru S, Jaju A, Manthri S, et al.

    Cureus 2021; (13(12)):e20086 doi:10.7759/cureus.20086.

    PMID: 34993034
  9. 9

    Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES.

    Ito T, Ramos-Alvarez I, Jensen RT

    Cancers 2023; (15(5)) doi:10.3390/cancers15051377.

    PMID: 36900170
  10. 10

    Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin B12 Deficiency in Zollinger-Ellison Syndrome (ZES) Patients.

    Ito T, Ramos-Alvarez I, Jensen RT

    International journal of molecular sciences 2024; (25(13)) doi:10.3390/ijms25137286.

    PMID: 39000391
  11. 11

    Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.

    Maideen NMP

    Chonnam medical journal 2023; (59(2)):115-127 doi:10.4068/cmj.2023.59.2.115.

    PMID: 37303818
  12. 12

    Hypertrophic Gastric folds with Hypomagnesemia, linking the dots.

    Zafar M, Muhammad T, Saher NU, Toqeer M

    Pakistan journal of medical sciences 2021; (37(4)):1237-1240 doi:10.12669/pjms.37.4.3984.

    PMID: 34290814
  13. 13

    Balancing therapeutic benefits and hidden risks of proton pump inhibitors in pediatric practice: a narrative review and update.

    Rogalidou M, Papadopoulou A

    Clinical and experimental pediatrics 2026; (69(3)):186-196 doi:10.3345/cep.2025.02761.

    PMID: 41736231
  14. 14

    Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of experience with somatostatin receptor positron emission tomography.

    Said M, Krogh J, Feldt-Rasmussen U, et al.

    Journal of neuroendocrinology 2023; (35(8)):e13322 doi:10.1111/jne.13322.

    PMID: 37564005
  15. 15

    Weight Gain in Zollinger-Ellison Syndrome After Acid Suppression.

    Riff BP, Leiman DA, Bennett B, et al.

    Pancreas 2016; (45(2)):193-7 doi:10.1097/MPA.0000000000000376.

    PMID: 26164604
  16. 16

    Zollinger-Ellison Syndrome: A Rare Case of Chronic Diarrhea.

    Aamar A, Madhani K, Virk H, Butt Z

    Gastroenterology research 2016; (9(6)):103-104 doi:10.14740/gr734w.

    PMID: 28058079
  17. 17

    Management of neuroendocrine tumor liver metastases.

    Harrelson A, Wang R, Stewart A, et al.

    American journal of surgery 2023; (226(5)):623-630 doi:10.1016/j.amjsurg.2023.08.011.

    PMID: 37657968
  18. 18

    Role of Interventional Oncology in the Management of Neuroendocrine Tumors: 2026 Update.

    DePietro DM, Soulen MC

    Current oncology reports 2026; (28(1)).

    PMID: 42658297

This gastrinoma survivorship information is for educational purposes only and does not constitute medical advice. Your neuroendocrine tumor team should personalize surveillance, PPI monitoring, and treatment decisions to your history.

Get notified when new evidence is published on gastrin-producing neuroendocrine tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.